ProHealth fibromyalgia Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

The best sleeping positions for pain

VIDEO: Anxiety: 11 Things We Want You to Understand

Is There a GERD—Fibro Connection?

Beyond pain in fibromyalgia: insights into the symptom of fatigue.

Chronic Pain, Loneliness, Depression and Suicide

Stair negotiation in women with fibromyalgia: A descriptive correlational study.

Things to Do When You're Mostly Housebound

Could a Diet Reduce the Pain in Fibromyalgia? A FODMAPS Study Suggests Yes

Is a Good Night's Sleep at the Top of Your Wishlist?

When Everybody has a Plan in Life Except You

 
Print Page
Email Article

Profile of adverse events with duloxetine [Cymbalta] treatment: a pooled analysis of placebo-controlled studies – Source: Drug Safety, May 1, 2010

  [ 58 votes ]   [ Discuss This Article ]
By S Brunton, et al. • www.ProHealth.com • April 22, 2010


The serotonin and noradrenaline (norepinephrine) reuptake inhibitor duloxetine [brand names Cymbalta, Yentreve] has been approved in the US and elsewhere for a number of indications, including psychiatric illnesses and chronic pain conditions.

Because the patient populations are diverse within these approved indications, and duloxetine is not yet approved for treatment of other conditions, we wanted to determine if adverse event profiles would differ among patients being treated for these various conditions.

To provide detailed information on the adverse events associated with duloxetine and to identify differences in the adverse event profile between treatment indications and patient demographic subgroups.

Data were analyzed from all placebo-controlled trials of duloxetine completed as of December 2008. The 52 studies included 17,822 patients (duloxetine n = 10 326; placebo n = 7496) with major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, osteoarthritis knee pain (OAKP), chronic lower back pain and lower urinary tract disorders.

The main outcome measures were rates of treatment-emergent adverse events (TEAEs) and adverse events reported as the reason for discontinuation.

• The overall TEAE rate was 57.2% for placebo-treated patients and 72.4% for duloxetine-treated patients (p = 0.001 or less).

• Patients with osteoarthritis knee pain had the lowest TEAE rate (placebo 36.7% vs duloxetine 50.2% (p = 0.01 or less),

• While patients with fibromyalgia had the highest rate (placebo 80.0% vs duloxetine 89.0% (p = 0.001 or less).

The most common TEAE for all indications was nausea (placebo 7.2% vs duloxetine 23.4% (p = 0.001 or less), which was predominantly mild to moderate in severity. No statistically significant treatment-by-subgroup interactions for age were found between placebo and duloxetine treatment for the most common TEAEs.

The rates of duloxetine-associated dry mouth and fatigue were greater in women than in men (13.1% vs 10.4%, interaction p = 0.004; and 9.4% vs 7.6%, interaction p = 0.03, respectively).

Duloxetine-associated dry mouth incidence was higher in Caucasians than non-Caucasians (13.2%, 11.0%, interaction p = 0.04).

Duloxetine treatment is associated with significantly higher rates of common TEAEs versus placebo, regardless of indication or demographic subgroup.

Differences across indications are likely to be attributable to the underlying condition rather than duloxetine, as suggested by the similar trends observed in placebo- and duloxetine-treated patients.

Source: Drug Safety, May 2010;33(5):393-407. PMID: 20397739, by Brunton S, Wang F, Edwards SB, Crucitti AS, Ossanna MJ, Walker DJ, Robinson MJ. Faculty Development, Cabarrus Family Medicine Residency, Concord, North Carolina, USA.





Post a Comment

Featured Products From the ProHealth Store
B-12 Extreme™ Optimized Curcumin Longvida® Hydroxocobalamin Extreme™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 Your Brain Needs for Detox & Sharpness
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
Fibro Freedom™ Fibro Freedom™
Soothes, Strengthens & Revitalizes
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Repair Damaged Mitochondria and Reduce Fatigue Up to 45% Repair Damaged Mitochondria and Reduce Fatigue Up to 45%
Looking for Energy? Turn to Plants. Looking for Energy? Turn to Plants.
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery
How Glutathione Can Save Your Life How Glutathione Can Save Your Life
Block food Cravings At Their Molecular Root Block food Cravings At Their Molecular Root

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map